175 related articles for article (PubMed ID: 38114960)
1. Net clinical benefit of oral anticoagulants in Asian patients with atrial fibrillation based on a CHA
Methavigul K; Chichareon P; Yindeengam A; Krittayaphong R
BMC Cardiovasc Disord; 2023 Dec; 23(1):623. PubMed ID: 38114960
[TBL] [Abstract][Full Text] [Related]
2. Stroke and Thromboembolism in Warfarin-Treated Patients with Atrial Fibrillation: Comparing the CHA2DS2-VASc and GARFIELD-AF Risk Scores.
Proietti M; Rivera-Caravaca JM; Esteve-Pastor MA; Marín F; Lip GYH
Thromb Haemost; 2021 Aug; 121(8):1107-1114. PubMed ID: 33296920
[TBL] [Abstract][Full Text] [Related]
3. Net clinical benefit of warfarin in individuals with atrial fibrillation across stroke risk and across primary and secondary care.
Allan V; Banerjee A; Shah AD; Patel R; Denaxas S; Casas JP; Hemingway H
Heart; 2017 Feb; 103(3):210-218. PubMed ID: 27580623
[TBL] [Abstract][Full Text] [Related]
4. Net clinical benefit of edoxaban versus no treatment in a 'real world' atrial fibrillation population: A modelling analysis based on a nationwide cohort study.
Blann AD; Banerjee A; Lane DA; Torp-Pedersen C; Lip GY
Int J Cardiol; 2015 Dec; 201():693-8. PubMed ID: 26379097
[TBL] [Abstract][Full Text] [Related]
5. [A comparison of CAS risk model and CHA
Deng JL; He L; Jiang C; Lai YW; Long DY; Sang CH; Jia CQ; Feng L; Li X; Ning M; Hu R; Dong JZ; Du X; Tang RB; Ma CS
Zhonghua Xin Xue Guan Bing Za Zhi; 2022 Sep; 50(9):888-894. PubMed ID: 36096706
[No Abstract] [Full Text] [Related]
6. Non-valvular atrial fibrillation patients with none or one additional risk factor of the CHA2DS2-VASc score. A comprehensive net clinical benefit analysis for warfarin, aspirin, or no therapy.
Lip GY; Skjøth F; Nielsen PB; Larsen TB
Thromb Haemost; 2015 Oct; 114(4):826-34. PubMed ID: 26223245
[TBL] [Abstract][Full Text] [Related]
7. Stroke and bleeding risk scores in patients with atrial fibrillation and valvular heart disease: evaluating 'valvular heart disease' in a nationwide cohort study.
Lip GYH; Jensen M; Melgaard L; Skjøth F; Nielsen PB; Larsen TB
Europace; 2019 Jan; 21(1):33-40. PubMed ID: 29986001
[TBL] [Abstract][Full Text] [Related]
8. Sex Differences in the Use of Oral Anticoagulants for Atrial Fibrillation: A Report From the National Cardiovascular Data Registry (NCDR
Thompson LE; Maddox TM; Lei L; Grunwald GK; Bradley SM; Peterson PN; Masoudi FA; Turchin A; Song Y; Doros G; Davis MB; Daugherty SL
J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28724655
[TBL] [Abstract][Full Text] [Related]
9. Contemporary Trends in Oral Anticoagulant Prescription in Atrial Fibrillation Patients at Low to Moderate Risk of Stroke After Guideline-Recommended Change in Use of the CHADS
Katz DF; Maddox TM; Turakhia M; Gehi A; O'Brien EC; Lubitz SA; Turchin A; Doros G; Lei L; Varosy P; Marzec L; Hsu JC
Circ Cardiovasc Qual Outcomes; 2017 May; 10(5):. PubMed ID: 28506981
[TBL] [Abstract][Full Text] [Related]
10. Stroke and Systemic Thromboembolism according to CHA
Lee KB; Kim TH; Park J; Park JK; Kang KW; Kim J; Park HW; Choi EK; Kim JB; Lee YS; Shim J; Joung B
Yonsei Med J; 2022 Apr; 63(4):317-324. PubMed ID: 35352882
[TBL] [Abstract][Full Text] [Related]
11. The HAS-BLED score has better prediction accuracy for major bleeding than CHADS2 or CHA2DS2-VASc scores in anticoagulated patients with atrial fibrillation.
Roldán V; Marín F; Manzano-Fernández S; Gallego P; Vílchez JA; Valdés M; Vicente V; Lip GY
J Am Coll Cardiol; 2013 Dec; 62(23):2199-204. PubMed ID: 24055744
[TBL] [Abstract][Full Text] [Related]
12. Comparison of CHADS2 and CHA2DS2-VASC anticoagulation recommendations: evaluation in a cohort of atrial fibrillation ablation patients.
Winkle RA; Mead RH; Engel G; Kong MH; Patrawala RA
Europace; 2014 Feb; 16(2):195-201. PubMed ID: 24036378
[TBL] [Abstract][Full Text] [Related]
13. Net Clinical Benefit of Oral Anticoagulation Among Older Adults With Atrial Fibrillation.
Shah SJ; Singer DE; Fang MC; Reynolds K; Go AS; Eckman MH
Circ Cardiovasc Qual Outcomes; 2019 Nov; 12(11):e006212. PubMed ID: 31707823
[TBL] [Abstract][Full Text] [Related]
14. Prognosis in patients with atrial fibrillation and CHA2DS2-VASc Score = 0 in a community-based cohort study.
Taillandier S; Olesen JB; Clémenty N; Lagrenade I; Babuty D; Lip GY; Fauchier L
J Cardiovasc Electrophysiol; 2012 Jul; 23(7):708-13. PubMed ID: 22268375
[TBL] [Abstract][Full Text] [Related]
15. Warfarin therapy for atrial fibrillation in general practice--is bleeding risk underestimated?
Bratland B; Hornnes MB
Tidsskr Nor Laegeforen; 2014 Jan; 134(2):175-9. PubMed ID: 24477151
[TBL] [Abstract][Full Text] [Related]
16. Long-Term Stroke Risk Prediction in Patients With Atrial Fibrillation: Comparison of the ABC-Stroke and CHA
Rivera-Caravaca JM; Roldán V; Esteve-Pastor MA; Valdés M; Vicente V; Lip GYH; Marín F
J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28729407
[TBL] [Abstract][Full Text] [Related]
17. Validation of a Modified CHA2DS2-VASc Score for Stroke Risk Stratification in Asian Patients With Atrial Fibrillation: A Nationwide Cohort Study.
Chao TF; Lip GY; Liu CJ; Tuan TC; Chen SJ; Wang KL; Lin YJ; Chang SL; Lo LW; Hu YF; Chen TJ; Chiang CE; Chen SA
Stroke; 2016 Oct; 47(10):2462-9. PubMed ID: 27625386
[TBL] [Abstract][Full Text] [Related]
18. GARFIELD-AF risk score for mortality, stroke, and bleeding within 2 years in patients with atrial fibrillation.
Fox KAA; Virdone S; Pieper KS; Bassand JP; Camm AJ; Fitzmaurice DA; Goldhaber SZ; Goto S; Haas S; Kayani G; Oto A; Misselwitz F; Piccini JP; Dalgaard F; Turpie AGG; Verheugt FWA; Kakkar AK;
Eur Heart J Qual Care Clin Outcomes; 2022 Mar; 8(2):214-227. PubMed ID: 33892489
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the CHADS2, CHA2DS2-VASc and HAS-BLED scores for the prediction of clinically relevant bleeding in anticoagulated patients with atrial fibrillation: the AMADEUS trial.
Apostolakis S; Lane DA; Buller H; Lip GY
Thromb Haemost; 2013 Nov; 110(5):1074-9. PubMed ID: 24048467
[TBL] [Abstract][Full Text] [Related]
20. Prescription Patterns and Outcomes of Patients With Atrial Fibrillation Treated With Direct Oral Anticoagulants and Warfarin: A Real-World Analysis.
Kattoor AJ; Pothineni NV; Goel A; Syed M; Syed S; Paydak H; Mehta JL
J Cardiovasc Pharmacol Ther; 2019 Sep; 24(5):428-434. PubMed ID: 31035795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
